Your browser doesn't support javascript.
loading
Identification of novel c-Kit inhibitors from natural sources using virtual screening and molecular dynamics simulations.
Elasbali, Abdelbaset Mohamed; Al-Soud, Waleed Abu; Elfaki, Elyasa Mustafa; Alanazi, Hamad H; Alharbi, Bandar; Alharethi, Salem Hussain; Anwer, Khalid; Mohammad, Taj; Hassan, Md Imtaiyaz.
Afiliação
  • Elasbali AM; Department of Clinical Laboratory Science, College of Applied Sciences-Qurayyat, Jouf University, Sakakah, Saudi Arabia.
  • Al-Soud WA; Health Sciences Research Unit, Jouf University, Sakakah, Saudi Arabia.
  • Elfaki EM; Department of Clinical Laboratory Science, College of Applied Sciences-Sakaka, Jouf University, Sakakah, Saudi Arabia.
  • Alanazi HH; Department of Clinical Laboratory Science, College of Applied Sciences-Qurayyat, Jouf University, Sakakah, Saudi Arabia.
  • Alharbi B; Department of Clinical Laboratory Science, College of Applied Sciences-Qurayyat, Jouf University, Sakakah, Saudi Arabia.
  • Alharethi SH; Department of Clinical Laboratory, College of Applied Medical Sciences, University of Hail, Hail, Saudi Arabia.
  • Anwer K; Department of Biological Science, College of Arts and Science, Najran University, Najran, Saudi Arabia.
  • Mohammad T; Department of Botany, C. M. Science College, L. N. Mithila University, Darbhanga, India.
  • Hassan MI; Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi, India.
J Biomol Struct Dyn ; : 1-13, 2023 Jul 04.
Article em En | MEDLINE | ID: mdl-37403288
The Mast/Stem cell growth factor receptor Kit (c-Kit), a Proto-oncogene c-Kit, is a tyrosine-protein kinase involved in cell differentiation, proliferation, migration, and survival. Its role in developing certain cancers, particularly gastrointestinal stromal tumors (GISTs) and acute myeloid leukemia (AML), makes it an attractive therapeutic target. Several small molecule inhibitors targeting c-Kit have been developed and approved for clinical use. Recent studies have focused on identifying and optimizing natural compounds as c-Kit inhibitors employing virtual screening. Still, drug resistance, off-target side effects, and variability in patient response remain significant challenges. From this perspective, phytochemicals could be an important resource for discovering novel c-Kit inhibitors with less toxicity, improved efficacy, and high specificity. This study aimed to uncover possible c-Kit inhibitors by utilizing a structure-based virtual screening of active phytoconstituents from Indian medicinal plants. Through the screening stages, two promising candidates, Anilinonaphthalene and Licoflavonol, were chosen based on their drug-like features and ability to bind to c-Kit. These chosen candidates were subjected to all-atom molecular dynamics (MD) simulations to evaluate their stability and interaction with c-Kit. The selected compounds Anilinonaphthalene from Daucus carota and Licoflavonol from Glycyrrhiza glabra showed their potential to act as selective binding partners of c-Kit. Our results suggest that the identified phytoconstituents could serve as a starting point to develop novel c-Kit inhibitors for developing new and effective therapies against multiple cancers, including GISTs and AML. The use of virtual screening and MD simulations provides a rational approach to discovering potential drug candidates from natural sources.Communicated by Ramaswamy H. Sarma.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article